Alpa Laboratories Limited (ALPA.BO)
INR 105.3
(1.4%)
INR 105.3
(1.4%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 136.65 Million INR | 8.1% |
| 2022 | 126.41 Million INR | -18.25% |
| 2021 | 154.63 Million INR | -6.62% |
| 2020 | 165.59 Million INR | 31.95% |
| 2019 | 125.5 Million INR | -10.6% |
| 2018 | 140.38 Million INR | 2.3% |
| 2017 | 137.23 Million INR | 5.24% |
| 2016 | 130.4 Million INR | -13.07% |
| 2015 | 150 Million INR | 99.54% |
| 2014 | 75.17 Million INR | -42.19% |
| 2013 | 130.04 Million INR | -2.24% |
| 2012 | 133.01 Million INR | -14.41% |
| 2011 | 155.41 Million INR | -4.48% |
| 2010 | 162.7 Million INR | -4.76% |
| 2009 | 170.82 Million INR | -24.62% |
| 2008 | 226.62 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 136.65 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 126.03 Million INR | 0.0% |
| 2023 FY | 136.65 Million INR | 8.1% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 158.83 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 126.41 Million INR | -18.25% |
| 2022 Q4 | 126.41 Million INR | 0.0% |
| 2021 Q4 | 154.63 Million INR | 0.0% |
| 2021 FY | 154.63 Million INR | -6.62% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 188.61 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 165.59 Million INR | 31.95% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 172.39 Million INR | 0.0% |
| 2020 Q4 | 165.59 Million INR | 0.0% |
| 2019 FY | 125.5 Million INR | -10.6% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 125.5 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 121.47 Million INR | 0.0% |
| 2018 Q4 | 140.38 Million INR | 0.0% |
| 2018 FY | 140.38 Million INR | 2.3% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 137.23 Million INR | 5.24% |
| 2016 FY | 130.4 Million INR | -13.07% |
| 2015 Q2 | 136.01 Million INR | 0.0% |
| 2015 FY | 150 Million INR | 99.54% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 75.17 Million INR | -42.19% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 112.7 Million INR | 0.0% |
| 2014 Q4 | 75.17 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 130.04 Million INR | -2.24% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 130.13 Million INR | 0.0% |
| 2013 Q4 | 130.04 Million INR | 0.0% |
| 2012 FY | 133.01 Million INR | -14.41% |
| 2012 Q4 | 133.01 Million INR | 0.0% |
| 2011 FY | 155.41 Million INR | -4.48% |
| 2011 Q4 | 155.41 Million INR | 0.0% |
| 2010 FY | 162.7 Million INR | -4.76% |
| 2009 FY | 170.82 Million INR | -24.62% |
| 2008 FY | 226.62 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 99.169% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.861% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 97.95% |
| Granules India Limited | 13 Billion INR | 98.949% |
| Indoco Remedies Limited | 3.53 Billion INR | 96.129% |
| Achyut Healthcare Limited | 568 Thousand INR | -23958.627% |
| Ajanta Pharma Limited | 8.28 Billion INR | 98.35% |
| Alkem Laboratories Limited | 26.61 Billion INR | 99.486% |
| Brooks Laboratories Limited | 96.1 Million INR | -42.187% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 94.003% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 90.513% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 88.463% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.785% |
| Eris Lifesciences Limited | 1.89 Billion INR | 92.771% |
| FDC Limited | 3.88 Billion INR | 96.486% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 99.456% |
| Gufic Biosciences Limited | 2 Billion INR | 93.184% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -30.672% |
| Ipca Laboratories Limited | 24.71 Billion INR | 99.447% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | 8.88% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -39.493% |
| Lasa Supergenerics Limited | 190.43 Million INR | 28.241% |
| Laurus Labs Limited | 18.45 Billion INR | 99.259% |
| Lupin Limited | 49.53 Billion INR | 99.724% |
| Mankind Pharma Limited | 15.53 Billion INR | 99.12% |
| Medicamen Biotech Limited | 593.75 Million INR | 76.985% |
| Medico Remedies Limited | 163.37 Million INR | 16.355% |
| Megasoft Limited | - INR | -Infinity% |
| NATCO Pharma Limited | 7 Billion INR | 98.049% |
| Piramal Pharma Limited | 21.75 Billion INR | 99.372% |
| RPG Life Sciences Limited | 1.01 Billion INR | 86.47% |
| Sigachi Industries Limited | 707.2 Million INR | 80.677% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.862% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 94.089% |
| Syncom Formulations (India) Limited | 210.81 Million INR | 35.179% |
| Unichem Laboratories Limited | 7.04 Billion INR | 98.061% |
| Wanbury Limited | 360.23 Million INR | 62.065% |
| Windlas Biotech Limited | 621.89 Million INR | 78.026% |
| ZIM Laboratories Limited | 812.62 Million INR | 83.184% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 99.603% |
| Sun Pharma Advanced Research Company Limited | - INR | -Infinity% |
| Divi's Laboratories Limited | 31.84 Billion INR | 99.571% |
| Hester Biosciences Limited | 755.81 Million INR | 81.92% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 87.476% |
| Amrutanjan Health Care Limited | 289.04 Million INR | 52.723% |
| Bal Pharma Limited | 878.11 Million INR | 84.438% |
| Strides Pharma Science Limited | 11.26 Billion INR | 98.787% |
| Venus Remedies Limited | 1.21 Billion INR | 88.77% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 97.874% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 98.073% |
| Shilpa Medicare Limited | 3.44 Billion INR | 96.038% |
| Aarti Drugs Limited | 4.85 Billion INR | 97.188% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 96.783% |
| Suven Life Sciences Limited | 7.08 Million INR | -1828.765% |
| Ind-Swift Limited | 640.91 Million INR | 78.678% |
| Valiant Laboratories Limited | 100.15 Million INR | -36.443% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 97.281% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 96.201% |
| Themis Medicare Limited | 705.74 Million INR | 80.637% |
| Hikal Limited | 3.03 Billion INR | 95.501% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 99.4% |
| Sequent Scientific Limited | 3.46 Billion INR | 96.053% |
| Novartis India Limited | 448.6 Million INR | 69.538% |
| Wockhardt Limited | 6.4 Billion INR | 97.865% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 98.94% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -435.957% |
| Neuland Laboratories Limited | 3.5 Billion INR | 96.1% |
| Morepen Laboratories Limited | 2.48 Billion INR | 94.503% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -242.66% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 88.947% |